Human Vaccines A Global Strategic Business Plan

1

Welcome

OMAHA, NEBRASKA. 6912 N. 97th Circle, Suite C,
Omaha, Nebraska 68122 . [phone]. FAX.
[phone] Production facilities 2721,
2704, 2720 84th Street. Omaha, Nebraska 68134
TEL. [phone]. [phone] e-mail
 admin_at_jn-vaccines.org UNITED STATES OF
AMERICA Subsidiaries JN-International Medical
Corp AFRICA 27 BP 71 Abidjan 27, Côte
d'Ivoire, Tel - Fax [phone]. South
East Asia          Singapore ,  Kuala Lumpur
2
Vaccines and diagnostics for today, hope for
tomorrow
Corporate Business Office 6912 North 97th
Circle, Omaha, NE 68122, USA. Tel. [phone]
Fax. [phone]. Web sites www.jnii-usa-bharat
.com www.jn-vaccines.org
3
Company Overview

• JN-International Medical Corporation was founded
  by a unique team of leading scientists graduated
  from University of California, Berkeley and
  Kansas State University, Manhattan, Kansas.
• Since the founding of the company in 1997, JN has
  focused its energies and based its success on
  innovative vaccines and diagnostics, sound
  business strategy, and a passion for people
  around the world, who receive our products.
• JN became one of the worlds leading
  biotechnology companies practicing world class
  medicine with our groundbreaking scientific
  discoveries, bringing to market with Innovative
  Vaccines and Diagnostics and proved the
  commercial viability of this new technology
  through recognition of our forward-thinking.

4

• Jeeri R. Reddy, MS., Ph.D. President/Scientific
  Director
• Peter Grotzinger, Operation Manager, USA
• Noel Kouame, MD. Medical Director and Regional
  Director, Africa
• Douti Laridja, MBA, Accountant
• Kalyan Reddy, B.S. (Industrial Engineering),
  Engineer
• Patrick Toe, Regional Rep. Sub-Sharon Africa
• Dana Orten, Ph.D. Quality Control Officer
• Barry Joseph, Ph.D. Chief Scientific Officer
• Sridhar V., M.Sc., M. Tech (Fermentation tech)
  Production Manager
• Scott D. Siebenborn, B.S. Production Facilities
  Manager
• Charles, Facility Engineer
• Amrit, B.S. Research Associate
• Honore , B.S. Research Associate
• Mr. Paramewarn, Director, Malaysia, South East
  Asia
• Mr. Ragu Thina , Singapore, Middle East and
  South Asia
• Consultants Dr. Carl Frasch, Former FDA

5
JN-International Medical Corporation Research
and Development Facility 6912 North 97th Circle,
Omaha, Nebraska 68122, USA.     
6
JN-International Medical Corporation
State-of-the-art Vaccine Facility c GMP and EU
and USDA approved facilities 2721, 2704, 2720
84th Street. Omaha, Nebraska 68134, USA.     
7
JN-International Medical Corporation
State-of-the-art Vaccine Facility c GMP and EU
and USDA approved facilities 2721, 2704, 2720
84th Street. Omaha, Nebraska 68134, USA.     
8
Mission Statement

• Our mission is to be the leading biotechnology
  company, using genetic engineering technology to
  discover, develop, and commercialize diagnostics
  and vaccines that address significant medical
  needs. We commit ourselves to high standards of
  integrity in contributing to the best interests
  of international communities, and to seeking
  significant returns, based on the continual
  pursuit of scientific and operational excellence.
  
• JN believes that this goal can be achieved by
  means of our product superiority, affordability
  and accessibility. Our organization has already
  achieved vaccine marketing success through a
  decade of unique as well as innovative research
  and technology combined with an innovative
  marketing strategy.

9
Objectives

• In pursuit of its mission, JN-Medical Corporation
  has been establishing a global presence. It can
  meet the needs of people in developing and
  emerging countries, which contribute to 80 of
  the world's population.
• At present, the vaccine requirement for the world
  is 1.3 billion doses for adolescent vaccines for
  the prevention of bacterial meningitis alone.
• In future, the company can offers the broadest
  range of vaccines, providing protection against
  both bacterial and viral diseases.

10
GLOBAL HEALTH

• Global Health Partners
• 1. Clinton Global Health Initiative
• 2. GBC 
• 3. Global Health Council
•  
• Global Health Association
• 1. Bill Melinda Gates Foundation
• 2. The Global Fund Organization
• 3. Médecins Sans Frontières
• 4. PATH
• 5. WHO
• 6. UNICEF

11
JN / Clinton Global Health InitiativeHIV / TB /
Malaria
12
Diagnostic Products

• Infectious Diseases
• HIV-1 and HIV-2
• Tuberculosis (TB)
• Hepatitis C (HCV)
• Malaria
• Pregnancy Detection (HCG)
• Urine Samples

13
JN-QC-TB Product CapabilitiesLateral Flow
Technology 2 minutes detection of \ HIV / TB /
Malaria for screening 1 million people per month
Test Line
Control Line
Wick
Sample
Conjugate
Negative Result
Positive Result
14
Diagnostic products distributed in 24 countries
throughout the world
Open Market
IN THE MARKET SINCE 1998
IN THE MARKET SINCE 2003
TO BE LAUNCHED
UNDER REGISTRATION
HIV/AIDS
TB
Epidemiological Studies
WHO/UNICEF EPIDEMELOGICAL STUDIES
15
HIV AND TB Epidemiological Studies

• Since 1997, JN developed and marketed the Rapid
  HIV and TB diagnostic test kits. These test kits
  are used in epidemiological screening studies in
  South Asia and South America by local governments
  in collaboration with World Health Organization
  (WHO) and UNICEF.
• Major HIV / TB Epidemiological Studies
• 1.  Malaysia - HIV project - 1 million
  women
• 2.  Bolivia  -  TB project - 2.5
  million children
• 3.  Kenya -  HIV project - 5 million
  people
• 4.  Singapore HIV project - 1 million
  women and men

16
Vaccine Division

• JN-International Medical Corporation which ranks
  among the worlds prominent biotech companies,
  specializes in the research, development of
  vaccines. These innovative products include
  vaccines for prevention of life threatening viral
  and bacterial diseases around the world.
• JN's innovative leadership in technology is the
  backbone of our philosophy. For example, while
  vaccines against a variety of infectious diseases
  represent one of the great triumphs of medicine,
  there are currently no vaccines available that
  are uniformly long lived for the prevention of
  diseases.
• JN displays its technical leadership by inventing
  mechanisms (DNA Vaccines) by which long lived
  humeral and cellular immune responses are
  generated and maintained in vivo. Our continuing
  work on future vaccines embodies JNs passionate
  pursuit for the eradication of diseases that
  plague mankind.

17
Vaccines Development Pipeline

• JN-International development pipeline has never
  been more robust and promising,  with the
  projects below under way, JN pipeline vaccines
  are composed of potential vaccines against
  Infectious (Hepatitis C and B), Sexually
  transmitted diseases (Herpes), Cancer and Stroke.
  
• JN's clinical trials are crucial to the
  exploration of new vaccines for developing
  countries that may address significant unmet
  disease prevention.
• JN's development pipeline continues to grow, now
  numbering over 13 vaccine projects. The pipeline
  is also balanced between breakthrough innovations
  and new indications for existing, well-understood
  products that may prevent from common diseases
  and disorders.

18
Vaccine Products Pipe-Line
Marketable Vaccines

• Meningococcal meningitis A,C,Y,W-135
  Polysaccharide and DT conjugate Vaccine 3rd and
  2nd Company in the World
• Stroke vaccine for adults Phase 1 1st
  Company in the World
• DNA Vaccine against Hepatitis C genotype-1 and
  Hepatitis B Phase 1 - 1st Company in the
  World
• Meningococcal meningitis Serotype-B - 2nd
  Company in the World
• HIV DNA vaccines -10th Company in the World
• DNA vaccine for Tuberculosis 1st Company in
  the World
• Cancer Vaccines Tumor and Colon Cancer - 15th
  Company in the World

In Human Trials
In Research and Development
19
IP Status

• Vaccine
• Patents
• Meningitis Vaccine
• Stroke Vaccine
• HIV Vaccine
• TB Vaccine
• 5. Hepatitis C Vaccine

20
Meningitis Vaccine for Africa

• Meningitis is an infection of the lining
  surrounding the brain and spinal cord
• Demand of 200 million doses per year in Africa
  alone
• In three years, JN will provide 60 million
  vaccines per year of our tetravalent
  Meningococcal meningitis A/C/Y/W-135
  polysaccharide diphtheria conjugate (DT) vaccine

21
Meningitis Vaccine demand Worldwide

• World Population at Meningitis risk

22
Child Deaths due to Meningitis Meningitis
A/C/Y/W-135 DT Conjugate Vaccine can save
millions of children worldwide
23
(No Transcript)
24
Stroke Vaccine
25
Stroke

• Stroke occurs when a blood vessel feeding the
  brain bursts or is clogged, causing a sudden
  disruption in the blood flow to the brain.
• Stroke is the third leading killer in the United
  States, resulting in the following statistics
  annually
• 750,000 victims
• 160,000 deaths (3rd leading cause of death)
• 266,000 survivors with permanent disabilities
• 30,000 new permanent admissions to nursing homes
• Over 4 million living survivors of stroke
• Every 45 seconds in the USA, someone has a stroke
  
• Huge economic impact with costs of 40-70
  billion per year

26
(No Transcript)
27
Efficacy of JNs Vaccine against Stroke

• A Stroke and Epilepsy vaccine developed by the
  JN-International generated auto-antibodies that
  targeted a specific brain protein induced a
  robust humoral response in mice and rats.
• A single dose of this vaccine was associated with
  strong anti-epileptic and neuro protective
  activity in rats for both a kainite-induced
  seizure model and also a middle cerebral artery
  occlusion stroke model at 1-5 months following
  vaccination.

28
Stroke Vaccine

• A. Stroke Un-Vaccinated (Left and Right
  pictures) and Vaccinated (Middle).
• B. Electroencephalographic (EEG) recordings

29
(No Transcript)
30
Hepatitis C Prevalence in the World WHO
statistics, there are 170 million people
infected with the hepatitis C virus, worldwide.
80 of acutely infected people progress to
chronic hepatitis and 20 of this population
develop cirrhosis.
31
Hepatitis B Prevalence in the WorldHepatitis B
virus infects 350 million people in the world and
kills 1 million annually
32
JN Hepatitis C and B Preventive and Therapeutic
Vaccines

• JNs Hepatitis B DNA vaccine (a single injection)
  can provide life-long protection against
  Hepatitis B infection compare to present
  Protein-based Hepatitis B vaccine, it requires
  two booster injections.
• There is no vaccine against Hepatitis C. JN first
  time in the world developed vaccine against
  Hepatitis C virus. A single dose vaccination can
  provide life long immunity.

33
JN DNA VaccinesPreventive and Therapeutic
Vaccine Immunologic Effect
34
Animal Trials of Hepatitis Vaccine

• On Mice and Monkeys

35
Preventive DNA Vaccines

• Intradermal vaccination of DNA induce antigen
  presenting cells in mucosa cells and produce
  antibodies to protect against Hepatitis viral
  infection

36
Life-long Protective Vaccines

• Protect DNA antigens from degradation as they
  transit through the stomach and small bowel
• Maintain immunogenicity and therapeutic activity

37
Oral DNA Vaccines

• DNA or peptide encapsulated with micro beads
  release the vaccine overtime to provide life time
  protection against Hepatitis infections.
• Protect peptides and proteins so they can be
  delivered by oral administration. Utilizes a
  gentle, all aqueous manufacturing technology that
  maintains the antigenicity of the protein

38
Human Clinical Trials

• Meningococcal meningitis human trials conducted
  in Niger and Burkina Faso in West Africa
• Meningococcal meningitis conjugate vaccine for
  children human trials is under way in Abidjan,
  Ivory Coast, West Africa

39
Stroke and Hepatitis Vaccine Trials

• Stroke Vaccine trials will be started in Iowa
  State Clinical Research Center.
• Meningitis Conjugate Vaccine for Children Trials
  Phase-3 completed in Ivory Coast.
• Hepatitis C trials shall be started in Ivory
  Coast.

40
Meningitis Trial staff in Sub-Sharon Africa
41

We thank you for attending our Presentation Look
forward to your visit us again! For More
Information about us visit our web site
www.jn-vaccines.org
OMAHA, NEBRASKA. UNITED STATES OF AMERICA
42
Our presence IS Your presence...

• Successfully different, we preserve the
  identity of our Partner !